Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GNRHR | P30968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26969704 | 0.93 | NPY5R (0.43) | NPY5RGNRHR | |
| SCHEMBL26969770 | 0.93 | NPY5R (0.40) | NPC1NPY5RHTTGAAGNRHR | |
| SCHEMBL26969740 | 0.93 | HTT (0.49) | NPC1NPY5RLMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL25274911 | 0.87 | NPY5R (0.43) | NPY5RALDH1A1GNRHR | |
| SCHEMBL25274228 | 0.87 | NPY5R (0.46) | NPY5RLMNASMN1; SMN2ALDH1A1ATM | |
| SCHEMBL26969692 | 0.87 | NPY5R (0.39) | NPY5RHTTGNRHR | |
| SCHEMBL26969720 | 0.84 | ACLY (0.40) | NPY5RSMN1; SMN2L3MBTL1ALDH1A1HTT | |
| SCHEMBL30733398 | 0.83 | ACLY (0.43) | NPY5RGNRHR | |
| SCHEMBL30733427 | 0.82 | ACLY (0.42) | NPY5RTSHRGNRHR | |
| SCHEMBL25239332 | 0.81 | NPY5R (0.47) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | NPC1 346/4885NPY5R 681/4885LMNA 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.